Bad Homburg, December 19, 2006

Attractive package for ALTANA shareholders: special dividend and dividend planned

  • Special dividend of €32 per share for ALTANA shareholders
  • Annual dividend 2006 of €1.30 per share planned

ALTANA AG (NYSE: AAA; FSE: ALT) announced at today’s Extraordinary General Meeting in Frankfurt that the net proceeds of the sale of the pharmaceuticals business will be transferred to shareholders in 2007 in the form of a special dividend. Based on the net proceeds as determined today, a special dividend of €32 per each dividend-bearing share (136 million shares) is expected. In addition ALTANA shareholders shall receive a dividend for the excellent financial year 2006. It is planned to propose a double-digit dividend increase to the Annual General Meeting – the eleventh double-digit dividend increase in succession – to expected €1.30 per share.

 “After distribution of the special dividend and dividend in May 2007, Altana shareholders will have the opportunity of investing in a high-growth chemicals business. Thus we are able to realize our announcement and offer our shareholders an attractive package as a result of the Group restructuring,“ commented Dr. Nikolaus Schweickart, President and CEO of ALTANA AG.

This press release contains forward-looking statements, i.e., current estimates or expectations of future events or future results. The forward-looking statements appearing in this press release include information on the financial year 2006 and the plans to propose to the shareholders at the annual general meeting in 2007 an increase of the dividend for the financial year 2006, information on ALTANA’s plans to transfer the net proceeds of the sale of the pharmaceutical business to the shareholders in 2007 by a special dividend as well as information on the expected amount of the dividend and the special dividend. These statements are based on beliefs of ALTANA’s management as well as assumptions made by and information currently available to ALTANA. Many factors that ALTANA is unable to predict with accuracy could cause ALTANA’s development, performance or achievements including the financial year 2006 as well as the dividend for the financial year 2006 and the special dividend to be materially different from those that may be expressed or implied by such forward-looking statements. These factors include the definite amount of the total purchase price and the net proceeds from the sale of the pharmaceutical business, final financial results of the business year 2006 and the decisions of ALTANA’s shareholders in the extraordinary and annual shareholders meeting.   
Forward-looking statements speak only as of the date they are made. ALTANA does not intend, and does not assume any obligation, to update forward-looking statements to reflect facts, circumstances or events that have occurred or changed after such statements have been made.

This press release is also available on the Internet at www.altana.com.